4//SEC Filing
Lazar David E. 4
Accession 0000921895-25-002082
CIK 0001130166other
Filed
Aug 3, 8:00 PM ET
Accepted
Aug 4, 7:23 PM ET
Size
5.6 KB
Accession
0000921895-25-002082
Insider Transaction Report
Form 4
Lazar David E.
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-07-30$12.36/sh−6,750$83,430→ 155,838 total
Footnotes (2)
- [F1]The number Shares owned by the Reporting Person is reflective of a 1-for-15 reverse stock split effected by the Issuer on July 7, 2025 (the "Reverse Stock Split").
- [F2]Due to an inadvertent ministerial error, the Form 4 filed by the Reporting Person on February 28, 2025 reported beneficial ownership of 354,738 shares of the Issuer's Series D Convertible Preferred Stock which had already been converted into 162,588 shares of Common Stock (after giving effect to the Reverse Stock Split) as of such date.
Documents
Issuer
Cyclacel Pharmaceuticals, Inc.
CIK 0001130166
Entity typeother
Related Parties
1- filerCIK 0001932843
Filing Metadata
- Form type
- 4
- Filed
- Aug 3, 8:00 PM ET
- Accepted
- Aug 4, 7:23 PM ET
- Size
- 5.6 KB